The first double-blind, randomized, placebo-controlled study was published in the New England Journal of Medicine. The researchers discovered that patients treated with the drug were on average sick for less time – an average of 11 days versus 15.
They also found some evidence that the drug appeared to slightly reduce severity of the disease, and to slightly reduce the fatality rate. There was no indication that Remdesivir could be used to completely cure COIVD-19. More studies are needed to determine effective dosing strategies to reduce severity and duration of illness, and to better understand the impact of the drug on different kinds of patients.
Pennsylvania State University